At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
In Brief
A Phase 2 clinical trial evaluating Carvedilol, Laboratory Biomarker Analysis, and 5 other interventions for Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm. Completed, enrolled 196 participants across 91 sites in 4 countries.
Detailed Summary
This phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn't get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can't pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Correlative studies
Correlative studies
Given PO
Ancillary studies
Ancillary studies